EI
NBIX icon

Ellevest Inc’s Neurocrine Biosciences NBIX Stock Holding History

Ellevest Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-121
Closed -$12.2K – 1164
2023
Q1 		$12.2K Buy
121
+41
+51% +$4.27K ﹤0.01% 981
2022
Q4 		$9.55K Buy
80
+22
+38% +$2.58K ﹤0.01% 1041
2022
Q3 		$6K Buy
58
+30
+107% +$3.04K ﹤0.01% 1144
2022
Q2 		$3K Buy
28
+3
+12% +$277 ﹤0.01% 1102
2022
Q1 		$2K Buy
25
+8
+47% +$678 ﹤0.01% 1204
2021
Q4 		$1K Sell
17
-21
-55% -$1.93K ﹤0.01% 1303
2021
Q3 		$4K Buy
+38
New +$3.59K ﹤0.01% 1015
2020
Q4 		– Sell
-18
Closed -$2K – 1292
2020
Q3 		$2K Hold
18
– – ﹤0.01% 918
2020
Q2 		$2K Hold
18
– – ﹤0.01% 899
2020
Q1 		$2K Buy
18
+11
+157% +$1.08K ﹤0.01% 780
2019
Q4 		$1K Hold
7
– – ﹤0.01% 826
2019
Q3 		$1K Buy
+7
New +$654 ﹤0.01% 430

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ellevest Inc's NBIX Position: Q2 2023 in Review

Ellevest Inc sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 121 shares — an estimated $12.2K sold.

Ellevest Inc first reported a position in NBIX in Q3 2019 and held it in 12 quarters. The position peaked at $12.2K in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Ellevest Inc reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 121 Neurocrine Biosciences shares in Q2 2023, an estimated $12.2K.
  • Ellevest Inc first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 12 quarters.
  • Ellevest Inc's Neurocrine Biosciences position peaked at $12.2K in Q1 2023.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.